SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
NeuroBo Pharmaceuticals, Inc. (NRBO) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NRBO
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-7.35
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-1,883.28 |
$0.00 |
$-14.59M |
- |
| 2017 |
$-2,421.73 |
$0.00 |
$-33.42M |
- |
| 2018 |
$-166.80 |
$0.00 |
$-23.64M |
- |
| 2019 |
$-1,030.50 |
$0.00 |
$-21.31M |
- |
| 2020 |
$-439.20 |
$0.00 |
$-29.68M |
- |
| 2021 |
$-157.85 |
$0.00 |
$-15.28M |
- |
| 2022 |
$-19.01 |
$0.00 |
$-13.97M |
- |
| 2023 |
$-2.46 |
$0.00 |
$-12.47M |
- |
| 2024 |
$-3.56 |
$0.00 |
$-27.59M |
- |
| 2025 |
$-7.35 |
$0.00 |
$-12.97M |
- |
